F Berenbaum

Summary

Country: France

Publications

  1. ncbi New horizons and perspectives in the treatment of osteoarthritis
    Francis Berenbaum
    Pierre and Marie Curie Paris 6 University, Department of Rheumatology, APHP Saint Antoine Hospital, 184 rue du Faubourg Saint Antoine, 75012 Paris, France
    Arthritis Res Ther 10:S1. 2008
  2. ncbi Targeted therapies in osteoarthritis: a systematic review of the trials on www.clinicaltrials.gov
    Francis Berenbaum
    Pierre and Marie Curie University Paris VI, AP HP Saint Antoine Hospital, Paris, France
    Best Pract Res Clin Rheumatol 24:107-19. 2010
  3. ncbi Diabetes-induced osteoarthritis: from a new paradigm to a new phenotype
    Francis Berenbaum
    Department of Rheumatology, Pierre and Marie Curie University, APHP Saint Antoine Hospital, Paris, France
    Postgrad Med J 88:240-2. 2012
  4. ncbi The quest for the Holy Grail: a disease-modifying osteoarthritis drug
    Francis Berenbaum
    Arthritis Res Ther 9:111. 2007
  5. ncbi Osteoarthritis year 2010 in review: pharmacological therapies
    F Berenbaum
    Pierre and Marie Curie University, AP HP, Saint Antoine Hospital, Paris, France
    Osteoarthritis Cartilage 19:361-5. 2011
  6. ncbi Diabetes-induced osteoarthritis: from a new paradigm to a new phenotype
    Francis Berenbaum
    Department of Rheumatology, Pierre and Marie Curie University, APHP Saint Antoine Hospital, Paris, France
    Ann Rheum Dis 70:1354-6. 2011
  7. ncbi Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis
    Karine Chauffier
    Department of Rheumatology, Pierre and Marie Curie University Paris VI, Saint Antoine Hospital, AP HP, 184, rue du Faubourg Saint Antoine, 75571 Paris Cedex 12, France
    Rheumatology (Oxford) 51:60-8. 2012
  8. ncbi [Pathophysiology of osteoarthritis: updated concepts]
    Francois Rannou
    Universite Paris Descartes, Hopital Cochin AP HP, Institut de Rhumatologie, Service de Rééducation, 75679 Paris Cedex 14, France
    Presse Med 39:1159-63. 2010
  9. ncbi Early referral to the rheumatologist for early arthritis patients: evidence for suboptimal care. Results from the ESPOIR cohort
    Bruno Fautrel
    Department of Rheumatology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75651 Paris Cedex 13, France
    Rheumatology (Oxford) 49:147-55. 2010
  10. ncbi Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial
    Martin Soubrier
    Department of Rheumatology, Hopital G Montpied, 63003 Clermont Ferrand, France
    Rheumatology (Oxford) 48:1429-34. 2009

Collaborators

Detail Information

Publications18

  1. ncbi New horizons and perspectives in the treatment of osteoarthritis
    Francis Berenbaum
    Pierre and Marie Curie Paris 6 University, Department of Rheumatology, APHP Saint Antoine Hospital, 184 rue du Faubourg Saint Antoine, 75012 Paris, France
    Arthritis Res Ther 10:S1. 2008
    ....
  2. ncbi Targeted therapies in osteoarthritis: a systematic review of the trials on www.clinicaltrials.gov
    Francis Berenbaum
    Pierre and Marie Curie University Paris VI, AP HP Saint Antoine Hospital, Paris, France
    Best Pract Res Clin Rheumatol 24:107-19. 2010
    ..Such a review should cover the majority of the ongoing or forthcoming trials in the disease. This review focusses on trials designed to test safety and/or efficacy of targeted therapies in osteoarthritis...
  3. ncbi Diabetes-induced osteoarthritis: from a new paradigm to a new phenotype
    Francis Berenbaum
    Department of Rheumatology, Pierre and Marie Curie University, APHP Saint Antoine Hospital, Paris, France
    Postgrad Med J 88:240-2. 2012
    ..If confirmed, this new paradigm will have a dramatic impact on prevention of OA initiation and progression...
  4. ncbi The quest for the Holy Grail: a disease-modifying osteoarthritis drug
    Francis Berenbaum
    Arthritis Res Ther 9:111. 2007
    ..Finally, a critical evaluation of the benefit/risk ratio of a drug must be carefully conducted and checked before and after launch. Well designed post-marketing surveillance is mandatory...
  5. ncbi Osteoarthritis year 2010 in review: pharmacological therapies
    F Berenbaum
    Pierre and Marie Curie University, AP HP, Saint Antoine Hospital, Paris, France
    Osteoarthritis Cartilage 19:361-5. 2011
    ..This review highlights a selection of original studies related to the treatment of osteoarthritis in 2010...
  6. ncbi Diabetes-induced osteoarthritis: from a new paradigm to a new phenotype
    Francis Berenbaum
    Department of Rheumatology, Pierre and Marie Curie University, APHP Saint Antoine Hospital, Paris, France
    Ann Rheum Dis 70:1354-6. 2011
    ..If confirmed, this new paradigm will have a dramatic impact on prevention of OA initiation and progression...
  7. ncbi Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis
    Karine Chauffier
    Department of Rheumatology, Pierre and Marie Curie University Paris VI, Saint Antoine Hospital, AP HP, 184, rue du Faubourg Saint Antoine, 75571 Paris Cedex 12, France
    Rheumatology (Oxford) 51:60-8. 2012
    ..To assess the effect of biotherapies vs placebo on fatigue in two situations: inadequate response to conventional treatments (IR-DMARD) and inadequate response to anti-TNF (IR-anti-TNF) in RA...
  8. ncbi [Pathophysiology of osteoarthritis: updated concepts]
    Francois Rannou
    Universite Paris Descartes, Hopital Cochin AP HP, Institut de Rhumatologie, Service de Rééducation, 75679 Paris Cedex 14, France
    Presse Med 39:1159-63. 2010
    ..Inflammation is a key regulator in osteoarthritis development and progression. The weight of genetic factors, mechanical stress, inflammation, and hormonal status is variable from a joint to another...
  9. ncbi Early referral to the rheumatologist for early arthritis patients: evidence for suboptimal care. Results from the ESPOIR cohort
    Bruno Fautrel
    Department of Rheumatology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75651 Paris Cedex 13, France
    Rheumatology (Oxford) 49:147-55. 2010
    ....
  10. ncbi Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial
    Martin Soubrier
    Department of Rheumatology, Hopital G Montpied, 63003 Clermont Ferrand, France
    Rheumatology (Oxford) 48:1429-34. 2009
    ..To compare this strategy with an initial combination of MTX and adalimumab (ADA) given for 3 months and then adjusted based on the disease activity status...
  11. ncbi Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients
    Abdolrasool Esmailzadeh
    Department of Dermatology Allergology, Tenon Hospital, Paris, France
    Dermatology 219:263-7. 2009
    ..Anti-tumor-necrosis-factor-alpha agents are limited by their side effects. Eczema is one of the most frequent adverse reactions affecting quality of life...
  12. ncbi [New nonsteroidal antiinflammatory drugs in rheumatoid arthritis]
    Francis Berenbaum
    Service de Rhumatologie, Hopital Saint Antoine, 184, rue du Faubourg Saint Antoine, 75012 Paris, France
    Ann Med Interne (Paris) 153:25-33. 2002
    ..Cyclooxygenase functions Fundamental aspects of coxibs Efficacy of coxibs in rheumatoid arthritis Tolerance to coxibs Conclusion..
  13. ncbi Crucial role of visfatin/pre-B cell colony-enhancing factor in matrix degradation and prostaglandin E2 synthesis in chondrocytes: possible influence on osteoarthritis
    Marjolaine Gosset
    UMR 7079, University Pierre and Marie Curie Paris VI, CNRS, Paris, France
    Arthritis Rheum 58:1399-409. 2008
    ..The present study was undertaken to investigate the contribution of visfatin, an adipose tissue-derived hormone, to the pathophysiology of OA, by examining its role in PGE2 synthesis and matrix degradation...
  14. ncbi Use of infliximab to treat psoriatic arthritis in HIV-positive patients
    Jeremie Sellam
    Rheumatology Department, Saint Antoine Teaching Hospital, AP HP, Paris, France
    Joint Bone Spine 74:197-200. 2007
    ..Potential long-term effects such as opportunistic infections, malignancies, and loss of HIV control need to be evaluated...
  15. ncbi Up-regulation of microsomal prostaglandin E synthase 1 in osteoarthritic human cartilage: critical roles of the ERK-1/2 and p38 signaling pathways
    Kayo Masuko-Hongo
    UMR CNRS 7079, , Paris, France
    Arthritis Rheum 50:2829-38. 2004
    ..We postulate that mPGES-1 may be a novel target for OA therapy...
  16. ncbi Signaling transduction: target in osteoarthritis
    Francis Berenbaum
    University Pierre and Marie Curie and Department of Rheumatology, UFR Saint Antoine, AP HP, Paris, France
    Curr Opin Rheumatol 16:616-22. 2004
    ..Targeting these signaling pathways in osteoarthritis is considered a novel approach to modulate this imbalance...
  17. ncbi Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy
    Jacques-Eric Gottenberg
    , Paris, France
    Arthritis Rheum 48:2019-24. 2003
    ....